glp 1 stories The GLP-1 story I thought I was telling — and the one I found Life After GLP-1: The Evidence-Based

No increase in number of adverse events with increasing renal or hepatic impairment was observed, and no new safety or tolerability findings with cagrilintide were identified with renal or hepatic impairment

No professional society guidelines currently recommend these therapies as standard of care for EBV infection

Interleukin-1 beta (IL-1), Interleukin-6 (IL-6), and Tumor Necrosis Factor-alpha (TNF-) are key pro-inflammatory cytokines involved in immune responses and inflammation

doi: 10.1016/j.mito.2020.05.004 67

The side effects experienced were mostly mild and did not affect quality of life, the researchers found